Erlotinib |
N-(3-ethylnylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
(CAS 183321-74-6) |
|
Description: |
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM). This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. The drug form of Erlotinib, Tarceva™, is used to treat certain forms of cancer, including non-small cell lung cancer.
|
Product No. |
KT20004 |
Product Name |
Erlotinib |
Synonyms |
NSC 718781; OSI-744; R-1415; OSI744; OSI 744; R1415; R 1415 |
Formal Name |
N-(3-ethylnylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine |
CAS Number |
183321-74-6 |
Molecular Formula |
C22H23N3O4 |
Formula Weight |
393.4 |
Formulation |
A crystalline solid |
Purity |
98%min |
Stability |
1 year |
Storage |
-20°C |
Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
Price & Availability |
In Stock. Price Negotiated. |
|
Related Products: |
AEE788
Afatinib
Afatinib dimaleate
AG 18
AG-1478
|
|